Six Previously Unreported Genes Linked to Risk of Developing Parkinson's Disease
By LabMedica International staff writers Posted on 13 Aug 2014 |
Image: Researchers used gene chips like this one to identify new genes that may be involved with the development of Parkinson\'s disease (Photo courtesy of the [US] National Human Genome Research Institute).
Genomic researchers have identified more than two dozen genetic risk factors implicated in the development of Parkinson's disease including six genetic loci that had not been reported previously.
Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) reviewed and collated data from genome-wide association studies (GWAS) in order to identify common variants in the genomes of 13,708 Parkinson's disease patients and 95,282 controls, all of European ancestry.
They reported the identification of 26 loci as having genome-wide significant association. These and six additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls. Using a sophisticated gene chip called NeuroX, the investigators confirmed that 24 variants represented genetic risk factors for Parkinson's disease, including six variants that had not been previously identified. The NeuroX gene chip incorporates approximately 24,000 common genetic variants thought to be associated with a broad spectrum of neurodegenerative disorders.
"The study brought together a large international group of investigators from both public and private institutions who were interested in sharing data to accelerate the discovery of genetic risk factors for Parkinson's disease," said contributing author Dr. Margaret Sutherland, a program director at the [US] National Institute of Neurological Disorders and Stroke. "The advantage of this collaborative approach is highlighted in the identification of pathways and gene networks that may significantly increase our understanding of Parkinson's disease. The replication phase of the study demonstrates the utility of the NeuroX chip for unlocking the secrets of neurodegenerative disorders. The power of these high tech, data-driven genomic methods allows scientists to find the needle in the haystack that may ultimately lead to new treatments."
The study was published in the July 27, 2014, online edition of the journal Nature Genetics.
Related Links:.
National Institutes of Health
Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) reviewed and collated data from genome-wide association studies (GWAS) in order to identify common variants in the genomes of 13,708 Parkinson's disease patients and 95,282 controls, all of European ancestry.
They reported the identification of 26 loci as having genome-wide significant association. These and six additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls. Using a sophisticated gene chip called NeuroX, the investigators confirmed that 24 variants represented genetic risk factors for Parkinson's disease, including six variants that had not been previously identified. The NeuroX gene chip incorporates approximately 24,000 common genetic variants thought to be associated with a broad spectrum of neurodegenerative disorders.
"The study brought together a large international group of investigators from both public and private institutions who were interested in sharing data to accelerate the discovery of genetic risk factors for Parkinson's disease," said contributing author Dr. Margaret Sutherland, a program director at the [US] National Institute of Neurological Disorders and Stroke. "The advantage of this collaborative approach is highlighted in the identification of pathways and gene networks that may significantly increase our understanding of Parkinson's disease. The replication phase of the study demonstrates the utility of the NeuroX chip for unlocking the secrets of neurodegenerative disorders. The power of these high tech, data-driven genomic methods allows scientists to find the needle in the haystack that may ultimately lead to new treatments."
The study was published in the July 27, 2014, online edition of the journal Nature Genetics.
Related Links:.
National Institutes of Health
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans